Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Calliditas Therapeutics AB CALT-5.231.06161.765.839.88%-22.25%53.30$9.20-$6.161$6.04

Detail of Calliditas Therapeutics AB

 
Employees
222
Industry
Biotechnology
Sector
Healthcare
Market cap
$2B

Company details

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation.

Revenue
CoG
Gross profit
OE
R&D
G&A
OTH
OI
PI
TAX
NI
Revenue (Rev)
$1.60B
Cost of goods (CoG)
-$104.68M
Gross profit (GP)
$1.50B
Operating expense (OE)
-$1.89B
Research and development (R&D)
-$557.91M
General and administrative (G&A)
-$1.31B
Other (OTH)
-$14.00M
Operating income (OI)
-$389.50M
Pretax income (PI)
-$468.32M
Tax (TAX)
-$12.04M
Net income (NI)
-$480.36M
Calliditas Therapeutics AB
CALT • XNGS • US
$6.04
-10.14 (-62.59%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.25
Payout ratio
21.70%
EPS
-$1.16
Margin profit
7.00%
52 week low
$4.00
52 week high
$41.549999
50-day simple moving average
$6.61
200-day simple moving average
$9.20
Percent held by insiders
87.59%
Percent held by institutions
5.67%
Dividend yield
4.21%

Change of shares

Cash vs Debt

Comparison of selected companies

 
%
Price change
CALT -62.62%
eps change
CALT 0.00%